Deerfield Management Company, L.P. (Series C) Terns Pharmaceuticals, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.86 - $8.19 $32,902 - $55,446	6,770 Added 39.16%	24,060 $157,000
Q4 2023 Feb 14, 2024	BUY	$3.37 - $6.86 $58,267 - $118,609	17,290 New	17,290 $112,000
Q2 2023 Aug 14, 2023	SELL	$7.35 - $13.29 $1.18 Million - $2.14 Million	-160,678 Reduced 7.8%	1,898,743 $16.6 Million
Q1 2023 May 15, 2023	SELL	$7.91 - $12.0 $6.26 Million - $9.5 Million	-791,866 Reduced 27.77%	2,059,421 $24.4 Million
Q4 2022 Feb 14, 2023	BUY	$4.62 - $10.18 $4.58 Million - $10.1 Million	991,287 Added 53.3%	2,851,287 $29 Million
Q3 2022 Nov 14, 2022	BUY	$1.87 - $6.42 $3.48 Million - $11.9 Million	1,860,000 New	1,860,000 $11 Million
Q2 2022 Aug 15, 2022	SELL	$1.5 - $3.0 $3.52 Million - $7.04 Million	-2,345,959 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$17.13 - $27.25 $40.2 Million - $63.9 Million	2,345,959 New	2,345,959 $51.6 Million

Others Institutions Holding TERN

# of Institutions

167

Shares Held

78.3M

Call Options Held

580K

Put Options Held

454K

Orbimed Advisors LLC San Diego, CA

7.56M
Shares

$45.1 Million
1.49% of portfolio
Vivo Capital, LLC Palo Alto, CA

6.9M
Shares

$41.1 Million
8.42% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

6.22M
Shares

$37.1 Million
4.41% of portfolio
Deep Track Capital, LP Greenwich, CT

5.58M
Shares

$33.2 Million
1.71% of portfolio
Black Rock Inc. New York, NY

4.12M
Shares

$24.6 Million
0.0% of portfolio

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $224M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account